Therapeutic Vaccines Market Outlook, Key Financials, Segmental Revenue and Geographical Revenue till 2026

Vaccines stimulate antibodies to help offer immunity against infectious and chronic diseases. Inactivated vaccines, subunit vaccines, recombinant vector vaccines, and DNA vaccines are some of the various types of vaccines. Therapeutic vaccine is a combination of biologics that are designed to develop immunity against the abnormal cells in the body. Therapeutic vaccines can be modified as per requirement and used in the treatment of various disorders and diseases such as cancer, HIV infectious diseases, and Alzheimer’s disease. Therapeutic vaccines induce strength in the immune response for the treatment of these disorders. Vaccines are prophylactic in nature and can induce therapeutic effects in prevention and treatment of various diseases, which increases adoption of vaccines, thereby aiding in growth of the therapeutic vaccines market.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/209

However, low availability of established therapeutic vaccines is expected to hinder growth of the therapeutic vaccine market. Increasing R&D is expected to support growth of the market.

Some therapeutic vaccines are especially formulated for the treatment of HIV infections. HIV virus weakens the immune system and its response towards various disease and abnormality causing agents. According to the U.S. Department of Health and Human Services, in 2010, there were various vaccines under phase 3 clinical trials, such as gp100 melanoma vaccine, Lucanix (Belagenpumatucel-L) (NovaRx Corp.) for NSCLC, GSK1572932A (GSK) for melanoma and NSCLC, and Stimuvax (Emepepimut-S) (Merck KGaA/Oncothyreon).

Therapeutic Vaccines Market Taxonomy:

By Vaccines Type

• Auto Immune Diseases Vaccines
• Neurological Disease Vaccines
• Cancer Vaccines
• Infectious Diseases Vaccines

By Indication

• Cancer
  • Breast Cancer
  • Prostate Cancer
  • Lung cancer
  • Melanoma
  • others
• Infectious Disease
  • HIV
  • Hepatitis B
  • Hepatitis C
  • Others
• Other Chronic Diseases
  • Alzheimer’s
  • Allergy
  • Others

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/209

Increasing demand for biologics and drugs for targeted therapies is expected to boost growth of the therapeutic vaccines market over the forecast period

Increasing prevalence of cancer, HIV infections, cardiovascular diseases, and various chronic diseases is expected to propel growth of the global therapeutic vaccines market. High prevalence of such diseases is expected to lead to increasing demand for biologic drugs for specific or targeted response, thereby aiding in growth of the therapeutic vaccines market over the forecast period. For instance, according to AVERT, a global organization involved in providing information and education on HIV and AIDS to the general population, in 2016, around 37 million people worldwide were infected by HIV and 40% were unaware about it. According to a report by America’s Biopharmaceutical Research Companies, in 2013, around 300 vaccines were in development, with research focused on prevention and treatment. These vaccines include treatment of various health issues and diseases such as allergy, cancer, infectious disease, and neurological disorder. Furthermore, according to data from the U.S. Centers for Disease Control and Prevention (CDC), therapeutic vaccines have led to the eradication of around 10 infectious diseases by up to 90% in the U.S.

Increasing R&D by major players is expected to boost growth of the therapeutic vaccines market over the forecast period

The global therapeutic vaccines market is competitive and highly fragmented. Merck and GlaxoSmithKline are considered to be one of the toughest competitors in the market due to their strong product pipeline under therapeutic vaccines segment. Key players in the market are focused on R&D to expand their product portfolio. For instance, Dendreon Corporation – a biotechnology company engaged in development, discovery and commercialization of novel therapeutic product – launched Provenge, the first U.S. FDA-approved immunotherapy drug for the treatment of prostate cancer.

To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/therapeutic-vaccines-market-209

Key players operating in the therapeutic vaccines market include Novartis AG, GlaxoSmithKline, Pfizer, Cytos Biotechnology AG, Argos Therapeutic Inc., Merck & Co., Dendreon Corp, Bavarian Nordic A/S, and Agenus, Inc.

Key Developments

• Key players in the market are focused on R&D of therapeutic vaccines to expand their market share. For instance, in September 2018, Morphogenesis, Inc., a U.S.-based immunotherapy company and Karolinska Institutet (KI) announced the commencement of a two and a half year collaboration combining Morphogenesis’ gene therapy with the exosome-mediated delivery technology developed by the KI Department of Medicine. This is expected to help to develop patient-specific vaccines for the treatment of several types of cancer.
• Moreover, Morphogenesis, Inc. is conducting human trials for its cancer vaccine, ImmuneFX for the treatment of severe cutaneous melanoma. The study is expected to be completed in November 2019.

Similarly, in April 2018, Pfizer Inc. received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its TRUMENBA (Meningococcal Group B Vaccine) for active immunization to prevent invasive disease caused by Neisseria meningitidis group B (MenB) in children ages 1 through 9 years.

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837